Preventing Rebound-Associated Fractures After Discontinuation of Denosumab Therapy: A Position Statement from the Health Insurance Committee of the Korean Endocrine Society

Overview

Journal Endocrinol Metab (Seoul)

Specialty Endocrinology

Date 2021 Sep 2

PMID 34474520

Citations 4

Authors

Bu Kyung Kim

Chong Hwa Kim

Yong-Ki Min

Affiliations

Soon will be listed here.

Citing Articles

Persistence with Denosumab in Male Osteoporosis Patients: A Real-World, Non-Interventional Multicenter Study.

Jeong C, Lee J, Kim J, Ha J, Jo K, Lim Y Endocrinol Metab (Seoul). 2023; 38(2):260-268.

PMID: 37150519 PMC: 10164495. DOI: 10.3803/EnM.2023.1663.

Long-term consequences of osteoporosis therapy with denosumab.

Bandeira F, de Oliveira L, Bilezikian J Arch Endocrinol Metab. 2022; 66(5):717-723.

PMID: 36382761 PMC: 10118828. DOI: 10.20945/2359-3997000000560.

Real-World Safety and Effectiveness of Denosumab in Patients with Osteoporosis: A Prospective, Observational Study in South Korea.

Rhee Y, Chang D, Ha J, Kim S, Lee Y, Jo E Endocrinol Metab (Seoul). 2022; 37(3):497-505.

PMID: 35654577 PMC: 9262695. DOI: 10.3803/EnM.2022.1427.

Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature.

Tay W, Tay D Endocrinol Metab (Seoul). 2022; 37(2):183-194.

PMID: 35417954 PMC: 9081316. DOI: 10.3803/EnM.2021.1369.

References

Niimi R, Nishihara A, Hasegawa M, Kono T, Sudo A . Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis. Osteoporos Int. 2017; 29(3):769-772. DOI: 10.1007/s00198-017-4334-3. View

Kendler D, Bone H, Massari F, Gielen E, Palacios S, Maddox J . Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int. 2019; 30(12):2437-2448. PMC: 6877701. DOI: 10.1007/s00198-019-05146-9. View

Leder B, Tsai J, Uihlein A, Wallace P, Lee H, Neer R . Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015; 386(9999):1147-55. PMC: 4620731. DOI: 10.1016/S0140-6736(15)61120-5. View

Brown J, Roux C, Torring O, Ho P, Jensen J, Gilchrist N . Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res. 2012; 28(4):746-52. PMC: 3617467. DOI: 10.1002/jbmr.1808. View

Kendler D, Chines A, Clark P, Ebeling P, McClung M, Rhee Y . Bone Mineral Density After Transitioning From Denosumab to Alendronate. J Clin Endocrinol Metab. 2019; 105(3). PMC: 7112973. DOI: 10.1210/clinem/dgz095. View

Shoback D, Rosen C, Black D, Cheung A, Murad M, Eastell R . Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. J Clin Endocrinol Metab. 2020; 105(3). DOI: 10.1210/clinem/dgaa048. View

Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen E, Guanabens N . Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone. 2017; 105:11-17. DOI: 10.1016/j.bone.2017.08.003. View

Camacho P, Petak S, Binkley N, Diab D, Eldeiry L, Farooki A . AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. Endocr Pract. 2020; 26(Suppl 1):1-46. DOI: 10.4158/GL-2020-0524SUPPL. View

Bone H, Bolognese M, Yuen C, Kendler D, Miller P, Yang Y . Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011; 96(4):972-80. DOI: 10.1210/jc.2010-1502. View

10.

Bone H, Wagman R, Brandi M, Brown J, Chapurlat R, Cummings S . 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017; 5(7):513-523. DOI: 10.1016/S2213-8587(17)30138-9. View

11.

Cummings S, San Martin J, McClung M, Siris E, Eastell R, Reid I . Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361(8):756-65. DOI: 10.1056/NEJMoa0809493. View